From COVID-19 to Cancer: The Next Chapter for mRNA

47 minutes ago
5 min read

Cancer treatment is entering an interesting new era, and one of the most promising ideas sounds almost futuristic: a vaccine designed specifically for an individual person's tumor.

Moderna, working with Merck, recently announced positive results from a large Phase 3 clinical trial testing a personalized mRNA cancer vaccine in people with high-risk melanoma. The results are significant, but there is an important detail to understand: the vaccine has not been shown to "cure" melanoma, and it is not yet an approved treatment.

What scientists have shown so far is that the treatment can help reduce the chances that melanoma comes back or spreads when it is used alongside an existing immunotherapy.

So how does a vaccine designed for one person's cancer actually work?

What makes cancer different?

Our cells contain DNA, which carries the instructions for building and maintaining our bodies. When cells become cancerous, their DNA can develop mutations, or changes in those instructions. Some of those mutations create unusual proteins that are found on cancer cells but not on most healthy cells. Scientists call these recognizable features neoantigens.

Neoantigens are like tiny molecular fingerprints, and iIf doctors can figure out which fingerprints are unique to a person's tumor, they can potentially teach that person's immune system to recognize cells carrying those fingerprints. That is where mRNA comes in.

What does mRNA have to do with it?

You may remember mRNA from the COVID-19 vaccines, but mRNA itself is not the thing that fights a disease. Messenger RNA, or mRNA, is more like a temporary set of instructions. Our cells naturally use mRNA to tell themselves how to make particular proteins. After the instructions have been used, the mRNA is broken down.

For a personalized cancer vaccine, scientists can use mRNA to give the immune system instructions for recognizing specific proteins associated with a patient's tumor. In other words, instead of giving everyone the exact same vaccine, researchers are trying to create a molecular wanted poster customized to the cancer in one particular person.

How do you make a vaccine for one person?

This is where the process gets especially interesting. Doctors remove the melanoma through surgery and collect a sample of the tumor. Scientists then sequence the tumor's genetic material and compare it with the patient's healthy cells. They look for mutations that could produce neoantigens that the immune system might recognize. The researchers then use that information to design an individualized mRNA vaccine.

The vaccine is not designed to prevent someone from developing melanoma in the first place. Instead, it is being tested as an adjuvant treatment, meaning it is given after the main treatment, such as surgery, to help reduce the chance that remaining cancer cells will cause the disease to return.

And there is another piece: Keytruda

Moderna's vaccine is being tested in combination with pembrolizumab, an immunotherapy sold under the brand name Keytruda. Pembrolizumab is a type of treatment called a checkpoint inhibitor. Cancer cells can sometimes take advantage of the immune system's natural "brakes" to avoid being attacked. Pembrolizumab helps release one of those brakes, allowing immune cells to respond more effectively.

The idea is powerful: Keytruda helps take the brakes off. The personalized mRNA vaccine helps point the immune system toward the target. Researchers are testing whether the combination can produce a stronger and longer-lasting immune response against cancer.

What did the new trial find?

The Phase 3 trial included 1,137 people with high-risk melanoma whose tumors had been surgically removed. Participants received either pembrolizumab alone or pembrolizumab combined with the personalized mRNA vaccine, called intismeran autogene, formerly known as mRNA-4157 or V940.

On August 19, 2026, Moderna and Merck announced that the Phase 3 trial met its primary goal. The combination significantly improved recurrence-free survival, meaning patients went longer without their cancer returning, compared with pembrolizumab alone. The treatment also reduced the risk of the cancer spreading to distant parts of the body or causing death.

The complete Phase 3 data have not yet been publicly released, so scientists and doctors will need to examine the detailed results before they can fully understand how large the benefit is and how it compares with other melanoma treatments.

That distinction matters.

A successful clinical trial is not the same thing as a cure. The companies have said they plan to discuss the results with regulatory agencies as they work toward possible approval.

Why is this such a big deal?

Cancer is not one single disease. There are hundreds of different types and subtypes, and even two people with the same type of cancer can have tumors with different mutations. That makes personalized medicine particularly interesting.

Instead of asking "What treatment works for melanoma?" scientists can begin asking: "What treatment works for this person's melanoma?"

The concept could eventually extend beyond melanoma. Moderna and Merck are studying the same general approach in several other cancers, including lung, bladder, and kidney cancers. But that does not mean the technology will automatically work for every cancer. Different cancers have different mutations and different relationships with the immune system. Each application has to be tested in clinical trials.

From pandemic technology to cancer treatment

The story is also a fascinating example of how scientific technology can move from one problem to another. mRNA became widely known because of COVID-19 vaccines, but scientists had been studying the technology for decades before the pandemic.

Now researchers are exploring whether the same basic technology can deliver instructions for fighting cancer.

The goal is not to create a universal "cancer vaccine."

It is something more complicated and, in some ways, more interesting: a system for rapidly creating a treatment based on the biology of an individual patient's tumor. That could be an important step toward medicine that is increasingly personalized.

So, is this a cancer cure?

Not yet. The new Phase 3 results are encouraging, and they represent an important milestone for personalized cancer vaccines. Earlier studies of the treatment had already shown promising reductions in melanoma recurrence and distant spread. A three-year follow-up of the earlier Phase 2 trial found that those benefits continued over time. But the latest Phase 3 announcement is still an early look at the complete results. More detailed data are needed, and regulatory review is still ahead.

What we can say right now is more precise: A personalized mRNA cancer vaccine, when combined with immunotherapy, has shown significant promise in helping prevent high-risk melanoma from returning or spreading.

And that is pretty remarkable on its own. The next question for scientists is an even bigger one: If we can teach the immune system to recognize one person's cancer, how many other cancers could we teach it to recognize?